At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
KBP-5074 0.25 mg tablet +1 moredrug
Likely dose
KBP-5074 0.25 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension
In Brief
A Phase 2 clinical trial evaluating KBP-5074 0.25 mg tablet and KBP-5074 0.5 mg tablet for Chronic Kidney Diseases and Hypertension. Completed, enrolled 162 participants across 2 sites.
Detailed Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Hypertension
CountriesUnited States
CollaboratorsWorldwide Clinical Trials
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedJul 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedJul 2, 2018
Enrollment StartApr 25, 2018
Primary CompletionAug 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8 years ago
Interventions
KBP-5074 0.25 mg tabletdrug
Oral administration, QD, 84 days
KBP-5074 0.5 mg tabletdrug
Oral administration, QD, 84 days